Maryland 2025 Regular Session

Maryland House Bill HB1109

Introduced
2/5/25  

Caption

Public Health Reform Act

Companion Bills

MD SB875

Crossfiled Public Health – Medetomidine and Xylazine Consumer Protection Act

Similar Bills

PA SB865

In miscellaneous provisions, further providing for urine drug screening requirement and providing for medetomidine awareness education.

MD HB417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

MD SB435

Public Health - Medetomidine and Xylazine Consumer Protection Act

SD HB1169

Classify medetomidine as a Schedule III controlled substance and establish permissible uses.

MD SB875

Public Health – Medetomidine and Xylazine Consumer Protection Act

NY A09001

Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.

NY S09221

Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.

PA SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.